Brian Mckittrick Email and Phone Number
Brian Mckittrick work email
- Valid
- Valid
Brian Mckittrick personal email
Brian Mckittrick phone numbers
Together with my colleagues at Merck and Schering-Plough, we contributed to 7 clinical candidates, 2 of which were approved by the FDA (Zetia and Victrelis). I am very proud of the work we did to develop a novel pharmacophore for inhibiting aspartyl proteases which we used to develop leads for BACE, HIV and Renin. The lead series in BACE ultimately led to the discovery of Verubecastat which advanced to phase 3 to test the amyloid mechanism of Alzheimer's disease. After I left Merck, the leads from the renin program also provided inhibitors of plasmepsin which are being developed for the treatment of malaria. In 2017 I joined OliPass, a Korean biotech company, developing drug candidates using the antisense modality with a novel platform of cell-penetrating peptide nucleic acids (OPNAs). The lead program targets Nav1.7 and has advanced to phase 2 human trials.In 2022, I moved into an advisory role at Olipass and I also joined the RISE program at Drew University. as a research fellow. I have set up my own lab doing early stage med chem projects working with Drew students and we are open to collaborations with biologists.
Research Institute For Scientists Emeriti (R.I.S.E) At Drew University
View-
Research FellowResearch Institute For Scientists Emeriti (R.I.S.E) At Drew UniversityNew Vernon, Nj, Us
-
AdvisorOlipass Corporation May 2022 - Present
-
AdvisorOlipass Corporation May 2019 - PresentNj And KoreaAt OliPass we are advancing the next generation of antisense therapeutics based on our proprietary OPNA platform of cell penetrating peptide nucleic acids.
-
Research FellowResearch Institute For Scientists Emeriti (R.I.S.E) At Drew University Jan 2022 - PresentCollaborative early stage med chem projects: 1) developing targeted protein degraders ( TPDs) using novel E3 ligases and 2) developing inhibitors of the taurine transporter to determine the effect of taurine on the development of resistance to chemotherapy treatment of ovarian cancer.
-
Drug Discovery ConsultantPipeline Partner Llc Mar 2017 - PresentMorris County NjPipeline Partner, LLC is a medicinal chemistry and drug discovery-focused consulting company providing experience and guidance with hit finding, lead identification, structure based optimization, target validation, medicinal chemistry, due diligence, intellectual property and related work.
-
Vp Of Science And StrategyOlipass Corp Apr 2017 - Apr 2022
-
Director Of Exploratory ChemistryMerck Nov 2009 - Nov 2016Rahway And Kenilworth NjLed an exploratory chemistry group which was focused on improving the way we do target and hit validation. This included the thorough triage and optimization of screening hits to provide high quality tool molecules to allow us to make rigorous go or no-go decisions on the projects. During this time, I continued to use structure-based drug design and applied these to a number of protease, kinase, and CYP450 targets. These projects were structure enabled and provided close collaborations with the computational chemists and X-ray crystallography groups at Merck. The development and use of QSAR models, visualization of X-ray structures and use of ligand docking programs proved very helpful in guiding the research. Additionally, we had the opportunity to develop predictive QSAR models and also to collaborate with Schrodinger to apply their free energy perturbation (FEP+) in real time to help guide lead optimization. -
Director Of Medicinal ChemistrySchering-Plough Research Institute 1986 - 2009Kenilworth, Nj1) 1986-1996: Lead identification and optimization focused on Cardiovascular and Central Nervous System targets. Highlights include being a co-inventor of Zetia, which was approved by the FDA in 2002 as a novel cholesterol-lowering agent. This was the first and only drug ever approved that blocks the NPC1L1 receptor and it became a multi-billion/year product. For this discovery we received several prestigious awards: the Thomas Alva Edison Patent Award, the Heroes of Chemistry Award (from by the American Chemical Association) and Inventor of the Year (from the Intellectual Property Owners Education Foundation). 2) 1996-2006: Built and led a group of 15 chemists dedicated to developing combinatorial chemistry. As part of this effort to make drug discovery more efficient we contributed to the Hepatitis C project, which ultimately led to Victrelis, which was the first HCV protease inhibitor approved by the FDA. Also, I contributed to the development of the CCR5 antagonist, which was advanced into man for the treatment of AIDS. Our contributions on this project were recognized with a second Thomas Alva Edison award. Subsequently, working with the computational chemistry group, we designed and developed a completely novel iminoheterocycle class of aspartyl protease inhibitors. For this we received the President’s Award for Discovery for pivotal contributions to the discovery of novel beta amyloid converting enzyme (BACE1) inhibitors, which led to clinical candidates for the treatment of Alzheimer’s disease. One of these, Verubecestat, is currently in Phase III. This brain penetrant small molecule may offer the best test to date of the amyloid hypothesis. We have since extended the use of the iminoheterocycle that we developed to other targets including orally active Renin inhibitors and we have redesigned these compounds to identify low nM leads for other aspartyl protease targets. -
Medicinal ChemistAyerst 1985 - 1986Synthetic Chemist working on potential backups to the anti-inflammatory agent Etodolac.Developed novel chemistry for functionalization of the 7 position of highly substituted indoles.
Brian Mckittrick Skills
Brian Mckittrick Education Details
-
Natural Product Synthesis And New Methodology -
Organic Chemistry -
Southampton College Of LiuMarine Science And Chemistry -
Organic Chemistry
Frequently Asked Questions about Brian Mckittrick
What company does Brian Mckittrick work for?
Brian Mckittrick works for Research Institute For Scientists Emeriti (R.i.s.e) At Drew University
What is Brian Mckittrick's role at the current company?
Brian Mckittrick's current role is Research Fellow.
What is Brian Mckittrick's email address?
Brian Mckittrick's email address is br****@****orp.com
What is Brian Mckittrick's direct phone number?
Brian Mckittrick's direct phone number is +190846*****
What schools did Brian Mckittrick attend?
Brian Mckittrick attended Cornell University, Brandeis University, Southampton College Of Liu, Brandeis University.
What skills is Brian Mckittrick known for?
Brian Mckittrick has skills like Drug Discovery, Drug Design, Medicinal Chemistry, Lead Change, Drug Development, Chemistry, Parallel Synthesis, Organic Chemistry, Pharmaceutical Industry, Gpcrs, Organic Synthesis, Oncology.
Not the Brian Mckittrick you were looking for?
-
Brian McKittrick
Seattle, Wa2kpmg.com, deloitte.com -
3gmail.com, fnal.gov, fnal.gov3 +163084XXXXX
-
Brian McKittrick
Assisting Self-Employed & Small Business Owners With Getting The Right Insurance Plan(S) For Their Needs & Budget. Making Insurance Simple & Affordable.Arlington, Tx3yahoo.com, healthreformteam.com, aol.com -
1siemens.com
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial